Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation.
OBJECTIVE
To assess analgesia use and the predictors for requiring analgesia in women undergoing medical abortion at all gestations up to 22 weeks.


METHODS
Retrospective observational study.


METHODS
Aberdeen Royal Infirmary, Scotland.


METHODS
Consecutive women undergoing medical abortion under the terms of the 1967 Abortion Act.


METHODS
Analgesia requirements and characteristics of women undergoing abortion were analysed using logistic regression.


METHODS
The effect of age, gestation, reproductive history, route and dose of misoprostol administration on analgesia requirements.


RESULTS
Of the total 4343 women included in this review, 3139 women (72%) required analgesia. Of these, 3054 women (97%) used oral analgesia, 75 women (2.4%) used opiates while 10 women (0.3%) had diclofenac sodium given rectally. There was no significant difference in analgesia use whether women used the vaginal or sublingual route of misoprostol administration. Logistic regression showed a significant positive association with gestation at termination (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.05-1.12), number of misoprostol doses used (OR 1.31, 95% CI 1.13-1.51) and induction to abortion interval (OR 1.08, 95% CI 1.03-1.12) and a negative association with the age of women undergoing abortion (OR 0.98, 95% CI 0.97-0.99) and previous live birth (OR 0.43, 95% CI 0.33-0.56).


CONCLUSIONS
Analgesia requirement was significantly higher in women of younger age, higher gestation, longer induction to abortion interval and with increased number of misoprostol doses used while women with previous live birth were significantly less likely to use analgesia.
Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital, Foresterhill, Cornhill Road, Aberdeen AB25 2ZD, Scotland, UK.
H
H
Hamoda
P W
PW
Ashok
G M M
GM
Flett
A
A
Templeton
D000020:Abortifacient Agents, Nonsteroidal; D000028:Abortion, Induced / Q000009:adverse effects*; D000328:Adult; D000698:Analgesia / Q000706:statistics & numerical data; D016362:Analgesia, Obstetrical / Q000706:statistics & numerical data; D000700:Analgesics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015735:Mifepristone; D016595:Misoprostol; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D012044:Regression Analysis; D012189:Retrospective Studies
D000020:Abortifacient Agents, Nonsteroidal; D000700:Analgesics; D016595:Misoprostol; D015735:Mifepristone